Developing aptamers into therapeutics.
作者信息
White R R, Sullenger B A, Rusconi C P
机构信息
Department of Surgery, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, North Carolina 27710, USA.
出版信息
J Clin Invest. 2000 Oct;106(8):929-34. doi: 10.1172/JCI11325.
Abstract
摘要
相似文献
1
Developing aptamers into therapeutics.
J Clin Invest. 2000 Oct;106(8):929-34. doi: 10.1172/JCI11325.
2
Nucleic acid aptamers as tools and drugs: recent developments.
Chembiochem. 2003 Oct 6;4(10):963-71. doi: 10.1002/cbic.200300648.
3
Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era.
Mol Interv. 2001 Apr;1(1):40-53.
4
Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application.
Thromb Haemost. 2005 Jun;93(6):1014-20. doi: 10.1160/TH04-12-0790.
5
Escort aptamers: a delivery service for diagnosis and therapy.
J Clin Invest. 2000 Oct;106(8):923-8. doi: 10.1172/JCI11324.
6
Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics.
Bioconjug Chem. 2009 Jun;20(6):1065-94. doi: 10.1021/bc800406a.
7
[Aptamers in clinical diagnostics].
Postepy Biochem. 2006;52(3):260-70.
8
Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA).
Chem Rev. 2007 Nov;107(11):4672-97. doi: 10.1021/cr050266u. Epub 2007 Oct 18.
9
Nucleic Acid Therapeutics for Neurological Diseases.
Neurotherapeutics. 2019 Apr;16(2):245-247. doi: 10.1007/s13311-019-00736-1.
10
Nucleic acid aptamers as adjuncts to vaccine development.
Curr Opin Mol Ther. 2006 Apr;8(2):122-9.
引用本文的文献
1
Using aptamers for targeted delivery of RNA therapies.
Mol Ther. 2025 Apr 2;33(4):1344-1367. doi: 10.1016/j.ymthe.2025.02.047. Epub 2025 Mar 5.
2
DNA Aptamer-Polymer Conjugates for Selective Targeting of Integrin α4β1 T-Lineage Cancers.
ACS Appl Mater Interfaces. 2025 Jan 22;17(3):4543-4561. doi: 10.1021/acsami.4c17788. Epub 2025 Jan 9.
3
Therapeutic Applications of Aptamers.
Int J Mol Sci. 2024 Jun 19;25(12):6742. doi: 10.3390/ijms25126742.
4
DNA-controlled protein fluorescence: Design of aptamer-split peptide hetero-modulator for GFP to respond to intracellular ATP levels.
Nucleic Acids Res. 2024 Aug 12;52(14):8063-8071. doi: 10.1093/nar/gkae532.
5
Towards better antivenoms: navigating the road to new types of snakebite envenoming therapies.
J Venom Anim Toxins Incl Trop Dis. 2023 Dec 18;29:e20230057. doi: 10.1590/1678-9199-JVATITD-2023-0057. eCollection 2023.
6
Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers.
J Am Chem Soc. 2023 Aug 2;145(30):16458-16463. doi: 10.1021/jacs.3c02752. Epub 2023 Jul 20.
7
Protein labeling and crosslinking by covalent aptamers.
Methods Enzymol. 2023;682:413-428. doi: 10.1016/bs.mie.2022.08.053. Epub 2022 Dec 24.
8
Aptamer-based rapid diagnosis for point-of-care application.
Microfluid Nanofluidics. 2023;27(2):15. doi: 10.1007/s10404-022-02622-3. Epub 2023 Jan 18.
9
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease.
J Cardiovasc Dev Dis. 2022 Dec 6;9(12):437. doi: 10.3390/jcdd9120437.
10
Therapeutic Potential of Aptamer-Protein Interactions.
ACS Pharmacol Transl Sci. 2022 Nov 4;5(12):1211-1227. doi: 10.1021/acsptsci.2c00156. eCollection 2022 Dec 9.
本文引用的文献
1
Blocking the initiation of coagulation by RNA aptamers to factor VIIa.
Thromb Haemost. 2000 Nov;84(5):841-8.
2
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.
J Clin Invest. 2000 Nov;106(10):1197-202. doi: 10.1172/JCI11631.
3
Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.
J Clin Invest. 2000 Nov;106(10):1189-95. doi: 10.1172/JCI11620.
4
Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model.
Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):E89-95. doi: 10.1161/01.atv.20.11.e89.
5
Therapeutic applications of transcription factor decoy oligonucleotides.
J Clin Invest. 2000 Nov;106(9):1071-5. doi: 10.1172/JCI11459.
6
Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Lancet. 1999 Oct 30;354(9189):1493-8. doi: 10.1016/S0140-6736(99)09405-2.
7
Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys.
J Chromatogr B Biomed Sci Appl. 1999 Sep 10;732(1):203-12. doi: 10.1016/s0378-4347(99)00285-6.
8
VEGF(165) mediates glomerular endothelial repair.
J Clin Invest. 1999 Oct;104(7):913-23. doi: 10.1172/JCI6740.
9
10
Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers.
Am J Pathol. 1999 Jan;154(1):169-79. doi: 10.1016/S0002-9440(10)65263-7.
Zotero 插件